Onconova Therapeutics and SymBio Pharmaceuticals have signed a licence agreement to develop and commercialise rigosertib in Japan and Korea.
Rigosertib, a styryl benzyl sulfone, is a small molecule inhibitor of critical pathways important in the growth and proliferation of cancer cells.
Onconova is conducting late-stage clinical trials with rigosertib in the US, Europe and India for the treatment of myelodysplastic syndromes and solid tumours.
Under the terms of the agreement, Onconova will receive an upfront payment and development milestones tied to the progress of rigosertib, as well as sales milestone payments and royalties based on net sales.
In addition to the intravenous product, an oral formulation of rigosertib is being developed for frontline myelodysplastic syndromes and other indications.